Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.
- Mechanism
- Curator reviewed
Heptabarbital (like all barbiturates) works by binding to the GABAA receptor at either the alpha or the beta sub unit. These are binding sites that are distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. This GABAA receptor binding decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons, while at the same time increasing burst duration and mean conductance at individual chloride channels; this increases both the amplitude and decay time of inhibitory postsynaptic currents. In addition to this GABA-ergic effect, barbiturates also block the AMPA receptor, a subtype of glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Heptabarbital also appears to bind neuronal nicotinic acetylcholine receptors.
- Primary indication
- Used mainly for sedation and hypnosis.Curator reviewed
- Formula / weight
- C13H18N2O3 · 250.2936 g/mol (avg)
- Also known as
- Heptabarb · Heptabarbitone
- Code names
- G 475
Resolves to
PAZQYDJGLKSCSI-UHFFFAOYSA-NSMILESCCC1(C(=O)NC(=O)NC1=O)C1=CCCCCC1What you can answer from here — as of September 13, 2026
Which drugs share a target with Heptabarbital, and which of those have an active Phase 3 trial?